The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Mechanism of Increased Fluconazole Resistance in Candida glabrata during Prophylaxis
Open accessAbstract
Candida glabrata can become resistant to fluconazole, causing persistent colonization and invasive infection during prolonged exposure to the drug. To determine the mechanism of resistance in this setting, weekly oropharyngeal cultures for C. glabrata were obtained over a 2-year period from hematopoietic stem cell transplant recipients who were receiving fluconazole prophylaxis. In 20 patients from whom at least two isolates of the same karyotype were obtained more than two weeks apart, fluconazole MICs doubled every 31 days on average. The mechanism of fluconazole resistance in isolates from the 14 of the 20 patients studied in whom MICs changed at least fourfold was studied. Cellular resistance was accompanied by increased drug efflux as measured by decreased accumulation of fluconazole and rhodamine 6G and increased abundance of transcripts from two drug transporters, CgCDR1 and PDH1. The rapidity and regularity of the rising resistance indicated that C. glabrata is able to upregulate drug efflux without losing the ability to maintain colonization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other transporter genes have been reported to be upregulated in azole-resistant C. glabrata (CgCDR1, CgCDR2 (formerly named PDH1) and CgSNQ2 (another ABC transporter)) [100–102], C. dubliniensis (CdCDR1 and CdCDR2) [103], C. krusei (ABC1 and 2) [104, 105], and C. tropicalis (CDR1-homologue) isolates [44].”
From Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents (2013) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736
Hunter, P. R., & Gaston, M. A. (1988) · Journal of Clinical Microbiology · doi:10.1128/jcm.26.11.2465-2466.1988 · Cited by 3,138
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Marr, K. A., Seidel, K., White, T. C., & Bowden, R. A. (2000) · The Journal of Infectious Diseases · doi:10.1086/315193 · Cited by 493
Self-citationSanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337
Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., & Diekema, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1723-1727.2002 · Cited by 231
Millon, L., Manteaux, A., Reboux, G., Drobacheff, C., Monod, M., Barale, T., & Michel-Briand, Y. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.4.1115-1118.1994 · Cited by 205
Miyazaki, H., Miyazaki, Y., Geber, A., Parkinson, T., Hitchcock, C. A., Falconer, D. J., Ward, D. J., Marsden, K. E., & Bennett, J. E. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1695 · Cited by 162
Self-citationMarr, K. A., White, T. C., van Burik, J. H., & Bowden, R. A. (1997) · Clinical Infectious Diseases · doi:10.1086/515553 · Cited by 145
Self-citationFluconazole resistance due to energy-dependent drug efflux in Candida glabrata
Parkinson, T., Falconer, D. J., & Hitchcock, C. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.8.1696 · Cited by 129
Electrophoretic karyotypes of clinically isolated yeasts of Candida albicans and C. glabrata
Asakura, K., Iwaguchi, S., Homma, M., Sukai, T., Higashide, K., & Tanaka, K. (1991) · Journal of General Microbiology · doi:10.1099/00221287-137-11-2531 · Cited by 110
Inducible Azole Resistance Associated with a Heterogeneous Phenotype in Candida albicans
Marr, K. A., Lyons, C. N., Ha, K. C., Rustad, T. R., & White, T. C. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.52-59.2001 · Cited by 106
Self-citationClark, F. S., Parkinson, T., Hitchcock, C. A., & Gow, N. A. R. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.2.419 · Cited by 101
Guennec, R. L., Reynes, J., Mallié, M., Pujol, C., Janbon, F., & Bastide, J.-M. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.10.2732-2737.1995 · Cited by 77
Function of Candida glabrata ABC transporter gene, PDH1
Izumikawa, K., Kakeya, H., Tsai, H., Grimberg, B., & Bennett, J. E. (2003) · Yeast · doi:10.1002/yea.962 · Cited by 67
Self-citationElectrophoretic karyotypes of Torulopsis glabrata
Kaufmann, C. S., & Merz, W. G. (1989) · Journal of Clinical Microbiology · doi:10.1128/jcm.27.10.2165-2168.1989 · Cited by 54
Barchiesi, F. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/41.5.541 · Cited by 37
Khattak, M. N., Burnie, J., Matthews, R., & Oppenheim, B. A. (1992) · Journal of Clinical Microbiology · doi:10.1128/jcm.30.8.2211-2215.1992 · Cited by 28
Electrophoretic Karyotyping and Triazole Susceptibility of Candida glabrata Clinical Isolates
Barchiesi, F., Francesco, L. F. D., Arzeni, D., Caselli, F., Gallo, D., & Scalise, G. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050255 · Cited by 18
Research works printed but not linked: 1
- Ausubel F. M. R. Brent R. E. Kingston D. D. Moore J. G. Seidman J. A. Smith and K. Struhl. 1998. Current protocols in molecular biology. John Wiley & Sons Somerset N.J.
Cited by
Sorted by citations
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“…able to develop high-level resistance after exposure to azole antifungals (Fidel et al., 1999; Lee et al., 2009) and is one of the most frequent species isolated in breakthrough infections from patients receiving azole prophylaxis (Bennett et al., 2004; Imhof et al., 2004; Hachem et al., 2008).”
BackgroundPfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 705
“Amphotericin B 5 4– 16 (4) NA 72 Voriconazole 5 0.”
BackgroundInfluentialEfflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
“glabrata clinical isolates is associated with increased expression of PDR ABC drug efflux pumps, in this case, CgCdr1p and CgPdh1p (also called CgCdr2p) (24, 309).”
BackgroundInfluentialAntifungal Resistance and New Strategies to Control Fungal Infections
Vandeputte, P., Ferrari, S., & Coste, A. T. (2011) · International Journal of Microbiology · doi:10.1155/2012/713687 · Cited by 531
“glabrata, CgCDR1 and CgCDR2 (formerly denoted PDH1) as well as SNQ2 (another ABC transporter coregulated with CgCDR1 and CgCDR2) are upregulated in azole-resistant clinical isolates and participate in azole resistance [114–118].”
BackgroundSionov, E., Lee, H., Chang, Y. C., & Kwon-Chung, K. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000848 · Cited by 479
Metadata
- Authors
- Bennett, J. E., Izumikawa, K., & Marr, K. A.
- Affiliations
- National Institutes of Health (US)
- University of Washington (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2004-05
- Volume
- 48
- Issue
- 5
- Pages
- 1773-1777
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC400565
- OpenAlex
- W2108027055
- Cited by
- 217
- References
- 20
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 2 · 2022: 6 · 2021: 7 · 2020: 6 · 2019: 10 · 2018: 11 · 2017: 10 · 2016: 7 · 2015: 10 · 2014: 15 · 2013: 17 · 2012: 11
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08ai001571-02)
- National Institute of Allergy and Infectious Diseases (AI01571)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida glabrata, fluconazole resistance, antifungal prophylaxis, hematopoietic stem cell transplant recipients, drug efflux, oropharyngeal colonization, invasive candidiasis
- MeSH terms
- Antifungal Agents, Candidiasis, Fluorescent Dyes, Karyotyping, Rhodamines, Blotting, Northern, Fluconazole, Electrophoresis, Gel, Pulsed-Field, Reverse Transcriptase Polymerase Chain Reaction, Drug Resistance, Fungal, Drug Resistance, Multiple, Fungal, Candida glabrata
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review